Geron falls as chief commercial officer set to leave

Geron

24/07/2024 13:54

** Geron's  GERN.O  shares down 8.4% premarket to $4.23
after commercial-stage biopharma firm announced upcoming exit of
its chief commercial officer
    ** Blood cancer focused firm late Tues said Anil Kapur to
depart on Aug 31 to pursue other interests
    ** Search for Kapur's successor underway, co said
    ** In the interim, COO Andrew Grethleinm will lead the
commercial organization, with support from board member Dawn
Carter Bir
    ** Early last month, Geron won first US FDA approval for its
injectable blood disorder drug under brand name Rytelo
    ** GERN shares ended 2023 at $2.11

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-646-279-6380))